- Previous Close
0.0000 - Open
0.1905 - Bid 0.1805 x --
- Ask 0.2399 x --
- Day's Range
0.1860 - 0.1905 - 52 Week Range
0.1166 - 0.5683 - Volume
10,000 - Avg. Volume
7,004 - Market Cap (intraday)
9.769M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3000 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company's principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
argentbiopharma.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: RGTLF
View MorePerformance Overview: RGTLF
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGTLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGTLF
View MoreValuation Measures
Market Cap
8.29M
Enterprise Value
8.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.99
Price/Book (mrq)
10.51
Enterprise Value/Revenue
15.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-108.57%
Return on Equity (ttm)
--
Revenue (ttm)
891.08k
Net Income Avi to Common (ttm)
-17.53M
Diluted EPS (ttm)
-0.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
702.87k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.22M